Development and post-marketing data suggest that some licensed ARV doses could be reduced. We assessed the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) following the administration of 3 different doses to HIV negative volunteers as a preliminary to the design of clinical trials to examine the safety and efficacy of novel dose regimens in HIV positive subjects.
Purpose of the study
Development and post-marketing data suggest that some licensed ARV doses could be reduced. We assessed the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) following the administration of 3 different doses to HIV negative volunteers as a preliminary to the design of clinical trials to examine the safety and efficacy of novel dose regimens in HIV positive subjects.
Methods
Following written consent, male and female volunteers were administered LPV/r 400/100 (2 LPV/r Meltrex 200/50 tablets; regimen 1), 200/150 (1 Meltrex tablet, 1 100mg ritonavir capsule; regimen 2), and 200/50 (1 Meltrex tablet; regimen 3) mg twice daily (BID) for 7 days sequentially. Each 7-day phase was separated by a 7-day wash-out period and LPV/r steady-state PK was assessed over 12 hours on the last day of each dosing phase (days 7, 21 and 35). PK parameters were compared using Phase 1 as reference by determining geometric mean ratios (GMR) and 90% confidence intervals (CI). Safety and tolerability were assessed throughout the study period.
Summary of results
Twenty-two subjects (8 female) were enrolled and completed the study. GM PK parameters (90% CI) of the 3 doses are shown in Table 1 .
LPV PK parameters in regimens 2 and 3 were lower: GMR ( 
